FDA greenlights Prenosis' AI solution for sepsis diagnosis: is this a paradigm shift in healthcare?

By Liza Laws

- Last updated on GMT

© Getty Images - sepsis bacteria in blood
© Getty Images - sepsis bacteria in blood

Related tags AI Data management Patient centricity Artificial intelligence Research

In a landmark development poised to reshape the landscape of medical diagnostics, the US Food and Drug Administration (FDA) has officially sanctioned Prenosis' pioneering artificial intelligence (AI) tool designed for the early detection of sepsis.

Prenosis, a player in the realm of health technology, has secured this milestone with the full authorization of its diagnostic software, which it says marks a watershed moment in the field of healthcare innovation.

Sepsis, a grave medical condition triggered by the body's heightened response to infection, has long posed quite a challenge to healthcare practitioners due to its rapid onset and elusive diagnostic markers. With mortality rates soaring and treatment options often constrained by delayed detection, the urgent need for a breakthrough in sepsis diagnosis has been palpable across the medical community.

The solution – the Sepsis ImmunoScore, is an AI-powered diagnostic tool, and the company says, it is meticulously engineered to expedite and enhance the identification of this life-threatening condition.

Using the power of artificial intelligence, Prenosis says its Sepsis ImmunoScore represents a ‘paradigm shift in the diagnostic approach to sepsis’. By amalgamating a comprehensive array of 22 distinct physiological parameters – ranging from temperature and heart rate to cell counts – the software empowers clinicians with a holistic assessment of a patient's sepsis risk profile in real-time, it says.

Precision and accuracy of clinical decision-making

The software should see off the days of laborious manual monitoring as it offers a streamlined, automated solution that not only expedites diagnosis but also augments the precision and accuracy of clinical decision-making.

The FDA's endorsement of the tool, bestowed through the De Novo pathway, highlights the significance of this technological breakthrough, Prenosis says. As the first of its kind to receive such regulatory acclaim, the tool, the company says sets a precedent for future innovations in the burgeoning field of AI-assisted medical diagnostics, paving the way for a new era of personalized, data-driven healthcare solutions.

When asked about Prenosis’ technology, Greg Bullington, CEO and co-founder of Magnolia Medical Technologies, who has a keen interest in such solutions, said: “Given that sepsis is the number one driver of costs, 30-day readmissions and death in hospitals nationwide, this FDA milestone is positive for patient safety.

“However, this advancement is not a complete ‘solution’ to the problems associated with diagnosing sepsis. Physicians still need accurate and timely blood tests to determine how best to treat bloodstream infections including sepsis. To that end, there are major initiatives afoot with CDC, CMS and Congress focused on continuing to improve the sepsis diagnostic toolkit available to physicians. Prenosis could be a valuable innovative addition.”

AI driven healthcare innovations

Prenosis stands alongside esteemed peers such as Johns Hopkins University and Epic Systems, who have also embarked on similar ventures in the realm of AI-driven healthcare innovations. However, the company says what sets it apart is not merely its technological prowess, but its unwavering commitment to safety, efficacy, and regulatory compliance. Through rigorous FDA collaboration and adherence to stringent safety protocols, Prenosis says it has demonstrated its dedication to upholding the highest standards of patient care and clinical excellence.

With the FDA's imprimatur in hand, Prenosis believes it is poised to usher in a new era of sepsis management, one ‘characterized by early intervention, improved patient outcomes, and enhanced healthcare delivery’.

As Sepsis ImmunoScore prepares for its nationwide rollout in hospitals across the United States and beyond, the company says the stage is set for a transformative revolution in disease diagnosis and treatment protocols. In the ever-evolving landscape of healthcare, Prenosis' pioneering achievement serves as a beacon of hope, heralding a future where the convergence of artificial intelligence and medicine unlocks unprecedented possibilities for healing and well-being.

Srinivasan Ramanujam is the founder and director at Deep Mind Systems and says with his background in SAS biostatistics, he would be valuable in understanding the research behind this AI tool.

Analyzing patient data faster

He said: “Being the first AI diagnostic tool for sepsis is a significant breakthrough. Sepsis is a complex condition with often vague symptoms, making early diagnosis challenging. An AI tool that can analyze various data points to predict or diagnose sepsis holds immense potential.

“AI could potentially analyze patient data faster and more comprehensively than traditional methods, leading to quicker and more accurate diagnoses. This could significantly improve patient outcomes in time-sensitive cases like sepsis.

“As a biostatistician, I'd be curious about the validation process for the AI model. How well does it perform in real-world settings compared to clinical trials? It will be crucial to monitor the tool's performance and effectiveness over time.

“Overall, this is a positive development for the field of AI in medicine. While I would likely use SAS for data analysis and clinical trial design, this AI tool could be a valuable addition to the diagnostic toolbox for sepsis.” 

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more